Osteopore Limited Converts Convertible Notes into 15.15 Million Shares with $50,000 Capital Injection

Osteopore's Focus and Market Position in Bone Regeneration

Osteopore Limited is an ASX-listed biomedical company dedicated to developing and commercialising innovative bone regeneration and tissue engineering products. Operating within the regenerative medicine sector, which has experienced increased investment and regulatory approvals, Osteopore's portfolio focuses on biomaterial solutions that aid bone healing and reconstruction in clinical and surgical settings. This positions the company in a specialised niche of the global medtech and biotechnology markets.

The company addresses a significant clinical need, as bone defects and injuries pose major healthcare challenges worldwide. Osteopore leverages advanced biomaterial science to develop solutions that promote natural bone healing, establishing itself within the regenerative medicine market, which continues to attract investor interest as clinical data and regulatory frameworks evolve across Australia, the Asia-Pacific region, and beyond.

Details of Convertible Notes Conversion and Capital Raise

On 23 July 2026, Osteopore converted one tranche of convertible notes under ASX code OSXAM into ordinary fully paid shares. This resulted in the issuance of 15,151,515 new ordinary shares (ASX:OSX) on the same date. This conversion represents a typical capital restructuring event where debt-like securities held by investors are exchanged for equity, effectively turning liabilities into shareholder capital.

The shares were issued at AUD 0.0033 each, amounting to a capital value of approximately AUD 50,000. This price reflects the agreed conversion terms between Osteopore and the convertible note holder. The new shares carry equal rights and privileges as existing ordinary shares from the issue date. After this transaction, 48 convertible notes of the OSXAM class remain outstanding and unquoted on the ASX.

Effect on Osteopore's Issued Share Capital

Following the quotation of these newly converted shares, Osteopore's total issued quoted ordinary share capital rises to 693,592,914 shares. This significant increase reflects the company's capital management strategy. The use of convertible note conversions is a common financing technique to refinance debt or provide investors with equity conversion rights negotiated during initial debt issuance.

Osteopore's capital structure also includes 11,785,000 unquoted performance rights, which may vest upon achieving operational or financial milestones. Additionally, 48 convertible notes (OSXAM class) remain outstanding and unquoted. This multi-class capital structure is typical for growth-stage biomedical companies, using performance rights to align management incentives and convertible instruments to offer flexible financing options.

Regulatory Compliance and ASX Quotation Filing

Osteopore submitted an Appendix 2A application to the ASX, the formal process for requesting quotation of newly issued or converted securities. This filing confirms compliance with ASX Listing Rules regarding the conversion and quotation of shares. The document details the number and class of securities, issue date, and conversion mechanics.

The Appendix 2A is a mandatory disclosure under ASX rules, ensuring transparency and allowing verification that all quotation requirements are met. Osteopore's submission on 23 July 2026 provides investors with authoritative information on the capital structure changes. The company's ACN is 630538957, and its ASX code is OSX. Compliance with these reporting obligations is essential for maintaining listed company status and accurate capital structure records.

Financing Strategy Using Convertible Securities in Biomedical Development

Convertible notes are a strategic financing tool commonly used by biomedical companies facing capital-intensive development. These hybrid instruments offer investors downside protection via debt-like features and upside potential through equity conversion rights. This structure appeals to investors supporting clinical development, regulatory approval, and commercialisation phases while managing risk.

Converting convertible notes into equity reduces Osteopore's debt and increases shareholder equity, improving financial metrics like debt-to-equity ratios. The AUD 50,000 capital injection from this conversion bolsters the company's cash resources, potentially funding product development, clinical trials, regulatory submissions, or commercial activities.

Performance Rights and Long-Term Incentive Alignment

Osteopore holds 11,785,000 unquoted performance rights, commonly used in biomedical firms to align management and employee incentives with shareholder goals. These conditional securities typically vest upon achieving specific milestones such as clinical trial completion, regulatory approvals, or revenue targets.

The substantial number of performance rights indicates Osteopore's commitment to linking compensation with corporate milestones, consistent with industry practices in regenerative medicine and biotech sectors. The vesting and potential quotation of these rights depend on meeting performance conditions during designated periods.

Capital Management in the Regenerative Medicine Industry

Osteopore's capital management, exemplified by this convertible note conversion, reflects financing dynamics in regenerative medicine. Companies developing biomaterial therapies require ongoing investment for product development, research, clinical trials, regulatory processes, and commercialisation across multiple markets. Utilizing equity, convertible notes, and performance rights provides flexibility to access diverse capital sources while managing dilution and control.

The capital raised through this conversion supports Osteopore's development programs, although specific uses were not disclosed. Investors typically monitor capital deployment efficiency, as it directly influences progress toward key milestones and market entry. This conversion is part of Osteopore's broader capital strategy, which may include equity raises, debt financing, and strategic partnerships.

Market Environment for Biomedical Financing and Investor Insights

The timing and structure of Osteopore's convertible note conversion align with broader trends in biomedical financing. Investor interest in regenerative medicine and tissue engineering remains strong, driven by advancing clinical data, regulatory progress, and market potential in bone regeneration and orthopedics. Nonetheless, the sector faces risks from clinical development, regulatory hurdles, and competition.

The AUD 0.0033 issue price reflects negotiated valuation based on market conditions and company progress at the time of the original note issuance. Investors should assess Osteopore's clinical developments, regulatory achievements, competitive positioning, and capital runway. The conversion signals debt refinancing and ongoing investor confidence in the company's growth trajectory.

Investor Considerations Post-Capital Restructuring

Following the quotation of the 15,151,515 shares, investors should track Osteopore's clinical trial updates, regulatory submissions, commercial partnerships, and management guidance on development timelines. Monitoring cash burn, capital runway, and future financing announcements is also important.

The share capital increase dilutes existing shareholders' equity claims but provides funds to advance development, potentially enhancing long-term value if used effectively. Investors should review quarterly and annual reports and material announcements regarding Osteopore's bone regeneration and tissue engineering initiatives, regulatory engagement, clinical progress, and commercial milestones. The company's ability to convert development successes into approvals and market presence will be key to shareholder value creation over time.